(UroToday.com) The ASCO 2020 Virtual Education Program featured a session highlighting molecular enrichment strategies in genitourinary cancer, including Arlene Siefker-Radtke, MD, discussing new approaches to molecular enrichment for urothelial carcinoma. Dr. Siefker-Radtke notes that there are several components that make a good biomarker:
- It is easily reproducible: anyone can do it, it’s not open to interpretation (everyone agrees), and it does not fluctuate or change
- It is beneficial: it predicts response in that it selects patients that should or should not receive specific therapy, and it predicts toxicity